Toumai® Surgical Robot Fluorescence Imaging System DFVision® Receives CE Mark

Shanghai, China – November 14, 2025 — DFVision® 3D Fluorescence Endoscope, the core imaging system of the Toumai® Multi-Port Laparoscopic Surgical Robot, has officially received CE certification. This latest regulatory milestone marks a major step forward for the internationalization of Chinese surgical robotics, further validating the innovation capabilities of domestically developed medical technologies and accelerating the Toumai® system’s commercial expansion across Europe and other high-end markets.

In complex oncological surgery, completely removing tumors and metastatic tissue is the key to long-term survival. However, conventional imaging and surgical techniques often fall short in identifying tumor margins, especially in small lesions, invasive cancers, or anatomically difficult regions. Traditional white-light imaging shows only anatomical structure and cannot reflect tissue function or pathology, leaving residual tumor risk that impacts patient outcomes.

The DFVision® fluorescence imaging system addresses these challenges with multiple breakthrough features:

• High-definition lesion detection and perfusion assessment: Equipped with eight real-time switchable fluorescence display modes, the system enables surgeons to precisely differentiate tumors from healthy tissue, assess vascular anatomy, and evaluate blood flow in high-difficulty procedures across multiple specialties.
• High-Resolution Signal Stability Across Full Depth of Field: Featuring ultra-sensitive 10⁻⁶-level optical filtering, DFVision® achieves both high fluorescence sensitivity and signal stability across the full depth of field. This allows accurate identification of low-dose, micro-metastatic lesions, supporting more complete and confident resections.
• Seamless image integration for enhanced decision-making: Using indocyanine green (ICG) as a contrast agent, DFVision® independently captures visible and near-infrared spectrums, fusing them in real-time with a proprietary dynamic gain algorithm. This produces clear, unified images showing both anatomical and functional data, such as perfusion and tumor margins, without the need for frequent image switching.

Together, these capabilities significantly enhance surgical precision, safety, and radicality, supporting better outcomes for patients while improving workflow efficiency for surgeons.

To date, the Toumai® surgical robot has received market access in more than 60 countries and regions, with commercial deployments in nearly 40 countries and over 15,000 multi-specialty procedures completed globally. These include more than 700 remote surgeries conducted across 20 countries, setting over 60 world-first clinical milestones. Toumai® is the world’s first and only surgical robotic system to support connectivity with 5G, low-Earth and geostationary satellites, and broadband networks, achievements that continue to drive its growing influence on the global stage.

With CE certification now secured for its fluorescence imaging system, Toumai® is positioned to further accelerate its penetration into advanced surgical markets. By delivering cutting-edge visualization tools and a next-generation surgical experience, it continues to uphold its mission: making complex surgery simpler, and more accessible, for patients around the world.

About MicroPort^® MedBot™   

Commenced its development for laparoscopic surgery robots in 2014, and officially established in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort^® MedBot™", stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort^®", stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort^® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, image-based navigation, and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of intelligent surgery.

More information is available at: www.medbotsurgical.com/en